MENU
SGMT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Sagimet Biosciences (SGMT) Ownership - Who owns Sagimet Biosciences?
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways... Show more
Profile
Industry
N/A
Address
155 Bovet Road
Phone
+1 650 561-8600
Employees
10
Web
https://www.sagimet.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
83.06M
P/E Ratio
N/A
Total Cash
151.25M
Projected Growth
N/A
Total Debt
78K
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
4.70
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
SGMT
Capitalization
83.1M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
151M
Total Cash/Share
4.70
Total Debt
78K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
156M
P/B Ratio
0.53
Cash Flow
N/A
Earnings
-1.45
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
3K
Current Ratio
34.30
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-54.45M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-35.46
Shares Held By Institutions
87.1M
Shares Outstanding - Current
32.2M
Total Liabilities
4.45M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-27.556
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
155 Bovet Road
Phone
+1 650 561-8600
Employees
10
Web
https://www.sagimet.com